Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of “Hold” from Analysts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has received an average recommendation of “Hold” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $8.4286.

A number of equities analysts have commented on the company. Truist Financial raised Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. Chardan Capital dropped their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Arcataur Capital Management LLC acquired a new position in Iovance Biotherapeutics in the 4th quarter worth $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. Motley Fool Asset Management LLC acquired a new stake in Iovance Biotherapeutics in the fourth quarter valued at $29,000. M&T Bank Corp acquired a new stake in Iovance Biotherapeutics in the 4th quarter valued at about $31,000. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Iovance Biotherapeutics by 169.1% during the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 7,269 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Stock Performance

Shares of IOVA opened at $4.23 on Monday. The stock has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $3.49. Iovance Biotherapeutics has a 1 year low of $1.70 and a 1 year high of $5.63. The stock has a market cap of $1.89 billion, a PE ratio of -4.45 and a beta of 0.70.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm’s revenue for the quarter was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.36) EPS. On average, sell-side analysts forecast that Iovance Biotherapeutics will post -0.62 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.